Free Newsletter
New NIH budget designed to spur cancer trials
The NIH is slated for a modest 3.2 percent budget hike for the next fiscal year in President Obama's newly proposed budget. But even with an extra billion dollars, the NIH will have $4 billion less to spend than it did this year after handing out a raft of research grants with money provided by the stimulus bill.
What does the budget offer? The NIH says that its $6 billion budget line for cancer research will spur 30 new trials in 2011 and double the number of new compounds in the pipeline by 2016, according to an analysis by Bloomberg. And there's a $222 million push on autism to help discover the genetic and environmental triggers of the disease.
"In this current economy, we have to applaud the president for recognizing the value of biomedical research," says Mark Lively, president of the Federation of American Societies for Experimental Biology. "While it could have been much worse, we also have to recognize that it's less than what NIH had to spend this year."
The proposed budget comes in at $32.1 billion for 2011, down from 2010's $36 billion total. Lively and others in the biomedical research field had been calling for much higher spending in 2011 to help make up for the largely flat funding the NIH had to grapple with in the Bush years.
- here's the article from Bloomberg
Related Articles:
NIH chief outlines payback on $10B research bonanza
Researchers uncover new ways to treat chronic infections
NIH seeds scientific networking projects with $27M
Stimulus money spurs biomedical research work
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: